This webconference is supported by an independent educational grant provided by Ascensia Diabetes Care.

(free) CME/CPE/CEUs-certified Program series on CGM Systems Sensors Sense

Role of BGM and CGM in Reducing Burden, Improving Outcomes in Diabetes: Accuracy • Confidence • Long-term Convenience

Thursday April 14, 2022
7pm ET | 6pm CT | 5pm MT | 4pm PT

Forward this Program Guide cgmEDUCATION.net/guide

Satish K. Garg, MD, MBBS, DM
Editor-in-chief Diabetes Technology & Therapeutics
Professor of Medicine and Pediatrics
Director Adult Program
Barbara Davis Center for Diabetes
University of Colorado
Denver, Colorado

Grazia Alepppo, MD, FACE, FACP
Associate Editor
Diabetes Technology & Therapeutics
Professor of Medicine
Director, Diabetes Education Program
Associate Chief for Clinical Affairs
Division of Endocrinology, Metabolism and Molecular Medicine
Feinberg School of Medicine Northwestern University
Chicago, Illinois

David T. Ahn, MD
Program Director
Hoag Medical Center
Mary & Dick Allen Diabetes Center
Newport Beach, California

As an expert in diabetes technology, Dr Ahn is serving to address questions about same, including CGM insertions.

CHAIRPERSON

Jointly provided by
cgmEDUCATION.net™
Consortium for Integrated Diabetes Device Education

>22,800 Members and growing | Multi-Award Winning Medical Education

This webconference is supported by an independent educational grant provided by Ascensia Diabetes Care.
INTENDED AUDIENCE
Diabetologists, Endocrinologists, Primary Care Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Certified Diabetes Care and Education Specialists, and other Health Care Professionals interested in the management of diabetes.

EDUCATIONAL OBJECTIVES
After participating in this program, learners will be better able to:
1. Recognize CGM and its clinical benefits as standard of care for all insulin-requiring regimens, regardless of mode of administration.
2. Identify CGM functionality, accuracy, efficacy and patient experience as well as novel data on next-generation systems and improved shared decision making.
3. Employ clinical and patient considerations in selecting BGMs/CGMs for informed diabetes management, optimizing patient outcomes.

ACCREDITATION AND DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and CogniMed Inc. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

Evolve Medical Education LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider approved by the California Board of Registered Nursing, Provider Number 17004 for 1.0 contact hours.

Accreditation Statement
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity is accredited for 1.0 home study contact hours (0.10 CEU) for pharmacists, ACPE UAN 0062-9999-22-097-H01-P (release date: April 14, 2022; expiration date: April, 2023). To claim credit, participants must sign-in/register and participate in the entire activity, engaging in all active learning activities and completing all required learning assessments. No partial credit will be issued. Participants must complete an online evaluation at http://copsclearningexpressco.com within 30 days (providing their correct NABP e-Profile ID and month/day of birth) in order to ensure credit is reported to the NABP CPE Monitor. Detailed instructions will be provided after participating in the activity. The CPE Monitor will automatically reject all credit claimed and reported greater than 60 days from the date of participation. Visit our website to contact us with any questions.

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Chair:
Satish K. Garg, MD, MBBS, DM has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Boards for: Medtronic, Novo-Nordisk, Bayer, Zealand, Lifescan Diabetes Institute and Eli Lilly. He has also received Research grants from Eli-Lilly, Novo-Nordisk, Merck, Lexicon, Medtronic, Dario, NCI, T1D Exchange, NIDDK, JDRF, Dexcom and Sanofi.

Faculty:
Grazia Aleppo, MD, FACE, FACP has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant for: Bayer, Dexcom, and Insulet. She has also received research support from Dexcom, Eli-Lilly, Fractyl Health and Insulet.

David T. Ahn, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support Consultant for: Ascensia Diabetes Care, Senseonics, Lilly Diabetes, Novo, Mannkind and Roche Diagnostics. He is on the speaker’s list for Lilly Diabetes, Novo Nordisk, Xeris Pharmaceutical and Zealand Pharma.

EDITORIAL
The Evolve staff and planners have no financial relationships with commercial interests. CogniMed staff and planners have no financial relationships with commercial interests.

Caitlin Mardis, PharmD, University of South Carolina School of Pharmacy has no financial relationships with commercial interests.

DISCLAIMER
This content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Evolve Medical Education LLC, the University of South Carolina College of Pharmacy, CogniMed Inc., or Ascensia Diabetes Care. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Jointly provided by Ascensia Diabetes Care.

This activity is supported by an independent educational grant provided by Ascensia Diabetes Care.
Go to cgMEDUCATION.net/QUERY
- or -
cgMEDUCATION.net home page
click the QueRY banner (mobile or desktop)

- Ask Questions to the Faculty
- Refer a Colleague
- Get CME/CPE/CEUs
- Download Materials/Slides
Satish K. Garg, MD, MBBS, DM

Editor-in-chief Diabetes Technology & Therapeutics

Professor of Medicine and Pediatrics

Director Adult Program

Barbara Davis Center for Diabetes

University of Colorado

Denver, Colorado

Satish K. Garg, MBBS, MD, DM is Professor of Medicine and Pediatrics at the Adult Clinic of the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine in Denver, Colorado. He joined the faculty of the Barbara Davis Center in 1992 and became the founder and director of the Adult Clinic. He established and holds two Garg Endowed Chairs (clinical and clinical research) at the University of Colorado Denver. His team is one of the top teams worldwide in clinical trials involving insulin analogues and novel methods of insulin delivery (pens, pumps, oral, buccal and inhaled) and non-insulin adjunctive treatment options for Type 1 Diabetes. Other areas of interest include: continuous glucose monitors, evaluating the accuracy of meters at high altitude, and artificial pancreas systems.

Dr Garg received a medical degree in medicine at Punjab University in Ludhiana, India, where he also completed a residency in internal medicine at Christian Medical College and Hospital. He completed fellowships in adult endocrinology and diabetes at the Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India, and in pediatric endocrinology and diabetes at the University of Colorado at Denver and Health Sciences Center. He is board certified in internal medicine and endocrinology and diabetes.

Dr Garg is the Editor in chief of Diabetes Technology and Therapeutics journal since 2006 and Chair of the planning committee for Clinical Therapeutics and New Technology area for 2007 and 2008.
Consortium for Integrated Diabetes Device Education

drgrazia aleppo graduated magna cum laude from the University of Catania School of Medicine, Catania, Italy; subsequently completed internship, residency and endocrinology fellowship at the University of Illinois at Chicago.

she is a professor of medicine in the division of endocrinology, metabolism and molecular medicine at the Feinberg School of Medicine Northwestern University Chicago, Illinois.

Dr. Grazia Aleppo's clinical interest and research interest is in diabetes, particularly in the implementation of diabetes technology such as insulin pump therapy and continuous glucose monitoring (CGM) therapy in clinical practice. She has participated in the major clinical trials on the use of CGM in various populations and was the protocol chair for the replace-bG clinical trial which lead to the approval of CGM therapy for medicare beneficiaries in the USA.

She has been very active in scholarly activities with over 50 publications and book chapters in peer reviewed journals.

She is the present Chair of the Endocrine Society Clinical Affairs Core Committee. Dr. Aleppo is also a fellow of the American College of Endocrinology and the American College of Physicians and a member of many professional societies, including the American Diabetes Association, the Endocrine Society, the American Association of Clinical Endocrinologists, and the American College of Physicians.

She serves on the editorial board of BMJ Open Diabetes and Research Care.

Dr. Aleppo is considered a prominent national key opinion leader in the field of diabetes technology, including insulin pumps, CGM systems and automated insulin delivery.

She has been very active in scholarly activities with over 50 publications and book chapters in peer reviewed journals.

She is the present Chair of the Endocrine Society Clinical Affairs Core Committee. Dr. Aleppo is also a fellow of the American College of Endocrinology and the American College of Physicians and a member of many professional societies, including the American Diabetes Association, the Endocrine Society, the American Association of Clinical Endocrinologists, and the American College of Physicians.

She serves on the editorial board of BMJ Open Diabetes and Research Care.

Dr. Aleppo is considered a prominent national key opinion leader in the field of diabetes technology, including insulin pumps, CGM systems and automated insulin delivery.

**Clinical and Patient Considerations in Selecting BGM & CGM Systems for Diabetes: Factors in Shared Decision Making**

**Grazia Aleppo, MD, FACE**

Associate Editor
Diabetes Technology & Therapeutics
Professor of Medicine
Director, Diabetes Education Program
Associate Chief for Clinical Affairs
Division of Endocrinology
Metabolism and Molecular Medicine
Feinberg School of Medicine Northwestern University
Chicago, Illinois

**Importance of BGM Accuracy**
- History of severe hypoglycemia or hypoglycemia unawareness
- Use a CGM device that requires calibration
- Pregnancy
- Insulin therapy
- Increased risk for hypoglycemia (insulin or insulin secretagogue therapy)

Dr. Grazia Aleppo graduated magna cum laude from the University of Catania School of Medicine, Catania, Italy; subsequently completed internship, residency and endocrinology fellowship at the University of Illinois at Chicago.

She is a professor of medicine in the division of endocrinology, metabolism and molecular medicine at the Feinberg School of Medicine, Northwestern University, Chicago. She is also the associate chief for clinical affairs in the same division and the medical director of the Northwestern Medicine Diabetes Training and Education Program.

Dr. Aleppo's clinical interest and research interest is in diabetes, particularly in the implementation of diabetes technology such as insulin pump therapy and continuous glucose monitoring (CGM) therapy in clinical practice. She has participated in the major clinical trials on the use of CGM in various populations and was the protocol chair for the replace-bG clinical trial which lead to the approval of CGM therapy for medicare beneficiaries in the USA.

**Key Factors In Individualized CGM Selection**

- Calibration
- Insurance Coverage/Cost
- Skin Sensitivity
- Patient Preference
- Sensor Life
- High/Low Alarms
- Data Sharing
- Remote Functionality
- Accuracy
- Adhesive Sensitivity
- Link w/Mobile Device
- Sensor Visibility/Discretion
- Predictive Alerts
- Insulin Pump Compatible

**Senseonics Eversense- Fluorescent Technology**

Interstitial Fluid enters sensor hydrogel

Indicator molecules fluorescence in response to glucose binding

Glucose molecules bind reversibly to indicator molecules

Fluorescent hydrogel

2 photodiodes measure intensity of fluorescing hydrogel

Electronic signal communicates to Transmitter every 5 minutes
Dr. David Ahn is an Endocrinologist specializing in Diabetes and Metabolism and currently serves as the Program Director of the Mary & Dick Allen Diabetes Center. He previously was an Assistant Clinical Professor at UCLA. Born and raised in Southern California, Dr. Ahn received his Medical Degree and completed a fellowship in Endocrinology at UC San Diego.

He is passionate about empowering people with Type 1 Diabetes, Type 2 Diabetes, Pre-Diabetes, and Gestational Diabetes to optimize their blood sugar control while minimizing the emotional burden of living with chronic disease. He is a national expert on diabetes technology, including continuous glucose monitors, insulin pumps, and smartphone apps.

In addition to being an expert in diabetes technology, including CGM monitors, insulin pumps and smartphone apps, Dr. Ahn has trained in the insertion procedure for the novel, 180-days subcutaneous CGM sensor, and has gained extensive expertise in this practice. As an expert in diabetes technology, Dr. Ahn is serving to address questions about same, including CGM insertions.
Consortium for Integrated Diabetes Device Education

>22,600 Members and growing

Multi-Award Winning Medical Education

Membership (Free) Benefits

- Email updates on latest CME programs/webcasts
- Early/Pre-registration for online and live meetings and programs
- Access to SpeakerReady slide lecture guide
- One-time log-in for all “members-only” site activities (optional)

Become a Member Now!
Go to cgmEDUCATION.net/member

Find a Clinician

Physicians and Patients easily find and connect with You!

Find a Clinician
Add Your Practice Now!
Go to cgmEDUCATION.net/find

Refer-a-Colleague

Would a colleague be interested in cgmEDUCATION.net?

Refer a Colleague Now!
Go to cgmEDUCATION.net/refer

Go to cgmEDUCATION.net/query
This activity is supported by an independent educational grant provided by Ascensia Diabetes Care.